Aktis Oncology AKTS
NASDAQ AKTS
$16.62 +0.34 (+2.09%)
At close: Nov 13, 2026 · 4:00 PM EST

Aktis Oncology (AKTS) Return on Assets [ROA] (2026)

Updated

Aktis Oncology (AKTS) reported Return on Assets [ROA] of -16.42% for Q3 2026, down 3.40 percentage points from the prior quarter.

Analysis

Aktis Oncology (AKTS) Return on Assets [ROA] (2026) Analysis & Trends

For FY2025, Aktis Oncology posted Return on Assets [ROA] of -21.59%.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROA (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn 19.00%
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn 8.08%
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn 7.32%
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn 1.87%
5 Novartis Ag 306.35 Bn 279.93 Bn - -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn 9.36%
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn 9.80%
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn -7.67%
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn 2.00%
10 Aktis Oncology 895.95 Mn 335.72 Mn - -16.42%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -16.42%
Jun 30, 2026 -13.48%
API Access

Aktis Oncology Return on Assets [ROA] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-assets-%5Broa%5D&ticker=AKTS&period=max&api_key=YOUR_API_KEY